(-)-Blebbistatin
Based on 28 publication(s) in Google Scholar
(-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle myosin II.
For research use only. We do not sell to patients.
- Purity: 98.68%
- CAS No.: 856925-71-8
- Formula: C18H16N2O2
- Molecular Weight:292.33
-
Storage:
4°C, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) (-)-Blebbistatin
More- Cell. 2024 Jun 20;187(13):3409-3426.e24. [Abstract]
- Circulation. 2024 Jan 16;149(3):227-250. [Abstract]
- Adv Fiber Mater. 2026 Feb 12.
- Cell Stem Cell. 2025 Apr 3;32(4):581-597.e11. [Abstract]
- Bioact Mater. 2025 Oct 28:56:455-467. [Abstract]
- Nat Commun. 2025 Nov 17;16(1):10060. [Abstract]
- Nat Commun. 2025 Aug 5;16(1):7190. [Abstract]
- Adv Sci (Weinh). 2025 Sep 17:e00358. [Abstract]
- Adv Sci (Weinh). 2022 May;9(13):e2104682. [Abstract]
- Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. [Abstract]
- Nat Chem Biol. 2026 Feb 13. [Abstract]
- Theranostics. 2019 Apr 13;9(9):2555-2571. [Abstract]
- Cell Death Dis. 2023 Oct 10;14(10):663. [Abstract]
- Cell Death Dis. 2023 Jun 28;14(6):379. [Abstract]
- Dev Cell. 2025 Jun 23;60(12):1751-1767.e9. [Abstract]
- Cell Rep. 2026 Mar 27;45(4):117150. [Abstract]
- Neural Regen Res. 2025 Jun 19. [Abstract]
- Anal Chem. 2017 Oct 17;89(20):10841-10849. [Abstract]
- J Cell Biol. 2021 Oct 4;220(10):e202010118. [Abstract]
- Fundam Res. 2021 Dec 23;2(1):37-47. [Abstract]
- Colloids Surf B Biointerfaces. 2019 Oct 1:182:110332. [Abstract]
- Int Immunopharmacol. 2025 Aug 23:164:115384. [Abstract]
- Nanomedicine (Lond). 2019 Mar;14(5):613-626. [Abstract]
- Am J Physiol Heart Circ Physiol. 2021 Aug 1;321(2):H412-H421. [Abstract]
- bioRxiv. 2026 Jun 26.
- Res Sq. 2026 Jan 9.
- SSRN. 2025 Jul 29.
- Patent. US20230050888A1.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
IF
-
IF
-
IF
-
WB
Biological Activity
IC50: 0.5 to 5 μM (myosin II)[1]
Blebbistatin potently inhibits several striated muscle myosins as well as vertebrate nonmuscle myosin IIA and IIB with IC50 values ranging from 0.5 to 5 μM. Smooth muscle myosin is only poorly inhibited (IC50=80 μM)[1]. Blebbistatin does not compete with nucleotide binding to the skeletal muscle myosin subfragment-1. The inhibitor preferentially binds to the ATPase intermediate with ADP and phosphate bound at the active site, and it slows down phosphate release. It blocks the myosin heads in a products complex with low actin affinity[2]. In culture-activated hepatic stellate cells, blebbistatin is found to change both cell morphology and function. Stellate cells become smaller, acquire a dendritic morphology and have less myosin IIA-containing stress fibres and vinculin-containing focal adhesions. Blebbistatin impairs silicone wrinkle formation, reduces collagen gel contraction and blocks endothelin-1-induced intracellular Ca2+ release. It promotes wound-induced cell migration[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 856925-71-8
-
Appearance Solid
-
Molecular Weight 292.33
-
Formula C18H16N2O2
-
Color Light yellow to yellow
-
SMILES
CC1=CC=C(N=C(N(C2=CC=CC=C2)CC3)[C@]3(O)C4=O)C4=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (28)
-
Journal Impact Factor
-
Most Recent
-
Cell
Osr2 functions as a biomechanical checkpoint to aggravate CD8+ T cell exhaustion in tumor. [Abstract]2024 Jun 20;187(13):3409-3426.e24. PMID: 38744281 -
Circulation
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. [Abstract]2024 Jan 16;149(3):227-250. PMID: 37961903 -
-
Cell Stem Cell
Mechano-oncogenic cytoskeletal remodeling drives leukemic transformation with mitochondrial vesicle-mediated STING activation. [Abstract]2025 Apr 3;32(4):581-597.e11. PMID: 39986274 -
Bioact Mater
Dynamic matrix engineering promotes nascent protein deposition to drive cell migration and expedite Re-epithelization in chronic wound. [Abstract]2025 Oct 28:56:455-467. PMID: 41216373 -
Nat Commun
RIOK2 kinase regulates the translocation of the FADD-RIPK1-Caspase-8 complex to the ER and the cleavage of Gasdermin D to drive pyroptosis. [Abstract]2025 Nov 17;16(1):10060. PMID: 41249793
(-)-Blebbistatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 17;16(1):10060. [Abstract]
In vitro kinase assay of p-MYL9 protein with or without RIOK2, RIOK2(D246A), or FADD. Riok2−/− iBMDMs were transfected with plasmids encoding Riok2 or Riok2(D246A) and treated with myosin II inhibitor (-)-Blebbistatin (50 μM, 0.5 hour), then stimulated with LPS/5z-7.
-
Nat Commun
Promoting implant osseointegration via the osteoblast-selective β-amino acid polymer strategy. [Abstract]2025 Aug 5;16(1):7190. PMID: 40764473 -
Adv Sci (Weinh)
Microfilament-Myosin II Regulates the Differentiation of Multinucleated Cysts into Oocytes and Influences Oocyte Developmental Potential in Mice. [Abstract]2025 Sep 17:e00358. PMID: 40959902 -
Adv Sci (Weinh)
Pharmacological Perturbation of Mechanical Contractility Enables Robust Transdifferentiation of Human Fibroblasts into Neurons. [Abstract]2022 May;9(13):e2104682. PMID: 35240008
(-)-Blebbistatin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 May;9(13):e2104682. [Abstract]
HFFs expressed TUJ1 and MAP2 after 7 days of Ble (20 μM) treatment.
(-)-Blebbistatin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 May;9(13):e2104682. [Abstract]
Immunocytochemistry of YAP subcellular localization in (−)-blebbistatin (Ble) (20 μM; 7 days)-treated human foreskin fibroblasts (HFFs) was performed.
-
Adv Sci (Weinh)
Heterogeneous Responses to Mechanical Force of Prostate Cancer Cells Inducing Different Metastasis Patterns. [Abstract]2020 Jun 17;7(15):1903583. PMID: 32775149
(-)-Blebbistatin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. [Abstract]
Fluorescence imaging of LNCaP cells treated with the F-actin inhibitor cytoskeleton B (CB), microtubule inhibitor nocodazole (NO), FAK inhibitor PF573288 (PF), ROCK inhibitor Y-27632 (Y), and myosin II (Myo-II) inhibitor (-)-blebbistatin ((-)Bl). After the cells were cultured on different substrates for 3 days, inhibitors were added and incubated for 24 h. (green, F-actin; scale bar, 25 µm).
(-)-Blebbistatin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. [Abstract]
Expression of CTC cluster-related (plakoglobin and CD44) and EMT-related (vimentin and E-cadherin, 4 days) proteins in LNCaP cells grown on different substrates after treatment with different inhibitors (Cytoskeleton B (CB), Nocodazole (NO), PF-573288 (PF), Y-27632 (Y), and (-)-Blebbistatin ((-) Bl)).
-
Nat Chem Biol
2026 Feb 13. PMID: 41688711 -
Theranostics
Regulation of ezrin tension by S-nitrosylation mediates non-small cell lung cancer invasion and metastasis. [Abstract]2019 Apr 13;9(9):2555-2571. PMID: 31131053 -
Cell Death Dis
Pyruvate kinase M2 regulates mitochondrial homeostasis in cisplatin-induced acute kidney injury. [Abstract]2023 Oct 10;14(10):663. PMID: 37816709 -
Cell Death Dis
Inhibition of TRPV4 remodels single cell polarity and suppresses the metastasis of hepatocellular carcinoma. [Abstract]2023 Jun 28;14(6):379. PMID: 37369706 -
Dev Cell
STAT3-controlled CHI3L1/SPP1 positive feedback loop demonstrates the spatial heterogeneity and immune characteristics of glioblastoma. [Abstract]2025 Jun 23;60(12):1751-1767.e9. PMID: 39933531 -
Cell Rep
Optogenetic mediated contractility enables reversible control of microglial morphology and migration in vivo. [Abstract]2026 Mar 27;45(4):117150. PMID: 41903137 -
Neural Regen Res
Bone marrow mesenchymal stem cells protect against cerebral amyloid angiopathy by enhancing neutrophil mitocytosis. [Abstract]2025 Jun 19. PMID: 40536954 -
Anal Chem
Multifrequency Optomechanical Stiffness Measurement of Single Adherent Cells on a Solid Substrate with High Throughput. [Abstract]2017 Oct 17;89(20):10841-10849. PMID: 28895727 -
J Cell Biol
Membrane-bound SCF and VCAM-1 synergistically regulate the morphology of hematopoietic stem cells. [Abstract]2021 Oct 4;220(10):e202010118. PMID: 34402812 -
Fundam Res
Pharmacological regulation of tissue fibrosis by targeting the mechanical contraction of myofibroblasts. [Abstract]2021 Dec 23;2(1):37-47. PMID: 38933917 -
Colloids Surf B Biointerfaces
2019 Oct 1:182:110332. PMID: 31325776 -
Int Immunopharmacol
Lactylation of MYH9 and its impact on FOXO3a/Bim signaling in sepsis-induced gut-vascular barrier injury. [Abstract]2025 Aug 23:164:115384. PMID: 40850198 -
Nanomedicine (Lond)
Mechanical cues modulate cellular uptake of nanoparticles in cancer via clathrin-mediated and caveolae-mediated endocytosis pathways. [Abstract]2019 Mar;14(5):613-626. PMID: 30816057 -
Am J Physiol Heart Circ Physiol
A novel system for mapping regional electrical properties and characterizing arrhythmia in isolated intact rat atria. [Abstract]2021 Aug 1;321(2):H412-H421. PMID: 34213393 -
-
-
-
Solvent & Solubility
DMSO : 10 mg/mL (34.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (3.42 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1 mg/mL (3.42 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Freshly isolated HSCs are replated on 96-well plate. At day 3, medium is replaced by serum-free medium and cells are starved overnight, treated with or without blebbistatin (25 μM) for 2 h followed by stimulation with platelet-derived growth factor-BB (20 ng/mL). After an overnight incubation, the WST-1 cell proliferation assay are performed[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4208 mL | 17.1040 mL | 34.2079 mL | 85.5198 mL |
| 5 mM | 0.6842 mL | 3.4208 mL | 6.8416 mL | 17.1040 mL | |
| 10 mM | 0.3421 mL | 1.7104 mL | 3.4208 mL | 8.5520 mL | |
| 15 mM | 0.2281 mL | 1.1403 mL | 2.2805 mL | 5.7013 mL | |
| 20 mM | 0.1710 mL | 0.8552 mL | 1.7104 mL | 4.2760 mL | |
| 25 mM | 0.1368 mL | 0.6842 mL | 1.3683 mL | 3.4208 mL | |
| 30 mM | 0.1140 mL | 0.5701 mL | 1.1403 mL | 2.8507 mL |
(-)-Blebbistatin Related Classifications
HY-13441 Related Classifications
Powered by Bioz